Moreover, analysis of primary samples from B-ALL pediatric patients after CD19 CAR-T therapy indicated a lower expression of death receptor signaling genes in a group of patients who did not respond to the treatment as compared to those who achieved complete remissions [122]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.